ABT-700 inhibits tumor growth in mice bearing gastric and lung cancer xenografts with MET amplification.41 A phase I study of ABT-700 alone and in combination with docetaxel, 5-fluoruracil, folinic acid, irinotecan and cetuximab (FOLFIRI/cetuximab) or erlotinib is ongoing in patients with advanced solid tumors that may have MET amplification or cMET overexpression (NCT01472016). The gene discussed is MET; the disease is lung cancer.